Sermorelin

ID: sermorelin

Aliases: SERMORELIN, SERMORELIN ACETATE, Geref, GHRH(1-29) amide

Type: compound

Route/form: subcutaneous injection in historical/compounded contexts

Status: withdrawn_legacy_or_compounded

Evidence level: early human

Best data tier: early human

Support scope: review/regulatory

Source types: regulatory_review, review

Linked sources: 2

Broad outcomes: Hormones / fertility / sexual health, Longevity / mitochondrial / redox, Muscle growth / performance / recovery, PEDs / AAS / thermogenics

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• GHRH receptor agonism
• pulsatile growth hormone release
• GH deficiency diagnostic/therapy context

Optimization domains

• growth hormone
• endocrine
• pediatrics
• anti aging

Research basis

• Sermorelin has clinical literature and regulatory history in pediatric GH-deficiency diagnosis/treatment contexts.
• Mechanistically it is upstream GHRH stimulation, so the most defensible claim is pituitary GH release when reserve is present.
• It is a useful comparator to somatropin because it depends on endogenous axis capacity rather than replacing GH directly.

Limits, risks, and missing evidence

• Adult wellness, anti-aging, recovery, or body-composition claims are much weaker than the pediatric GH-deficiency context.
• Response depends on pituitary reserve and baseline GH/IGF physiology.
• GH-axis adverse effects and monitoring remain relevant.

Risk flags

• endocrine axis
• gh igf1 axis
• pediatric context
• outcome extrapolation

Linked papers, labels, and reviews

1. FDA Federal Register: sermorelin acetate was not withdrawn from sale for reasons of safety or effectiveness
   regulatory_review / govinfo_sermorelin_not_withdrawn_2013
   Regulatory history for sermorelin/Geref.
2. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
   review / pubmed_sermorelin_gh_deficiency_review_1999
   Clinical review in pediatric GH deficiency; not adult wellness evidence.